CA2637644A1 - Traitement de syndromes de detresse respiratoire aigus - Google Patents
Traitement de syndromes de detresse respiratoire aigus Download PDFInfo
- Publication number
- CA2637644A1 CA2637644A1 CA002637644A CA2637644A CA2637644A1 CA 2637644 A1 CA2637644 A1 CA 2637644A1 CA 002637644 A CA002637644 A CA 002637644A CA 2637644 A CA2637644 A CA 2637644A CA 2637644 A1 CA2637644 A1 CA 2637644A1
- Authority
- CA
- Canada
- Prior art keywords
- surfactant
- patients
- phospholipid
- patient
- calfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 title abstract description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 title abstract 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title description 12
- 239000004094 surface-active agent Substances 0.000 claims abstract description 54
- 206010069351 acute lung injury Diseases 0.000 claims abstract description 22
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 20
- 230000001419 dependent effect Effects 0.000 claims abstract description 4
- 229940026290 calfactant Drugs 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 19
- 230000001154 acute effect Effects 0.000 claims description 14
- 238000005399 mechanical ventilation Methods 0.000 claims description 7
- 229940066294 lung surfactant Drugs 0.000 claims description 6
- 239000003580 lung surfactant Substances 0.000 claims description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 5
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 206010038687 Respiratory distress Diseases 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims 2
- 108010007131 Pulmonary Surfactant-Associated Protein B Proteins 0.000 description 28
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 description 28
- 239000000902 placebo Substances 0.000 description 27
- 229940068196 placebo Drugs 0.000 description 27
- 238000006213 oxygenation reaction Methods 0.000 description 14
- 231100000517 death Toxicity 0.000 description 10
- 230000034994 death Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 238000009423 ventilation Methods 0.000 description 10
- 201000004193 respiratory failure Diseases 0.000 description 8
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 7
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 description 7
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 5
- 102000006410 Apoproteins Human genes 0.000 description 4
- 108010083590 Apoproteins Proteins 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000009429 distress Effects 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 206010011985 Decubitus ulcer Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 201000010878 atypical lipomatous tumor Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000002640 oxygen therapy Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000022752 well-differentiated liposarcoma Diseases 0.000 description 2
- DJMUYABFXCIYSC-UHFFFAOYSA-N 1H-phosphole Chemical compound C=1C=CPC=1 DJMUYABFXCIYSC-UHFFFAOYSA-N 0.000 description 1
- 241000014654 Adna Species 0.000 description 1
- 206010003598 Atelectasis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
- 208000022553 Parenchymal lung disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 238000002680 cardiopulmonary resuscitation Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- OYIKARCXOQLFHF-UHFFFAOYSA-N isoxaflutole Chemical compound CS(=O)(=O)C1=CC(C(F)(F)F)=CC=C1C(=O)C1=C(C2CC2)ON=C1 OYIKARCXOQLFHF-UHFFFAOYSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 229940063649 survanta Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76125006P | 2006-01-23 | 2006-01-23 | |
| US60/761,250 | 2006-01-23 | ||
| USPCT/US2006/02423 | 2006-01-23 | ||
| PCT/US2006/002423 WO2007084136A2 (fr) | 2006-01-23 | 2006-01-23 | Traitement du sras |
| PCT/US2007/060902 WO2007087524A2 (fr) | 2006-01-23 | 2007-01-23 | Traitement de syndromes de detresse respiratoire aigus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2637644A1 true CA2637644A1 (fr) | 2007-08-02 |
Family
ID=38089182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002637644A Abandoned CA2637644A1 (fr) | 2006-01-23 | 2007-01-23 | Traitement de syndromes de detresse respiratoire aigus |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1976535A2 (fr) |
| JP (1) | JP2009526763A (fr) |
| KR (1) | KR20080090442A (fr) |
| AU (1) | AU2007208145A1 (fr) |
| BR (1) | BRPI0706723A2 (fr) |
| CA (1) | CA2637644A1 (fr) |
| IL (1) | IL192121A0 (fr) |
| WO (1) | WO2007087524A2 (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2253003T3 (es) * | 1998-11-10 | 2006-05-16 | Altana Pharma Ag | Equipo de tratamiento que contiene composiciones a base de agentes tensioactivos pulmonares. |
| CA2463459C (fr) * | 2001-10-11 | 2013-06-18 | Altana Pharma Ag | Nouvelle utilisation de surfactant pulmonaire |
-
2007
- 2007-01-23 WO PCT/US2007/060902 patent/WO2007087524A2/fr active Application Filing
- 2007-01-23 BR BRPI0706723-2A patent/BRPI0706723A2/pt not_active Application Discontinuation
- 2007-01-23 KR KR1020087017896A patent/KR20080090442A/ko not_active Application Discontinuation
- 2007-01-23 AU AU2007208145A patent/AU2007208145A1/en not_active Abandoned
- 2007-01-23 EP EP07717366A patent/EP1976535A2/fr not_active Withdrawn
- 2007-01-23 CA CA002637644A patent/CA2637644A1/fr not_active Abandoned
- 2007-01-23 JP JP2008552543A patent/JP2009526763A/ja active Pending
-
2008
- 2008-06-12 IL IL192121A patent/IL192121A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007208145A1 (en) | 2007-08-02 |
| EP1976535A2 (fr) | 2008-10-08 |
| JP2009526763A (ja) | 2009-07-23 |
| WO2007087524A2 (fr) | 2007-08-02 |
| IL192121A0 (en) | 2008-12-29 |
| WO2007087524A3 (fr) | 2007-10-18 |
| KR20080090442A (ko) | 2008-10-08 |
| BRPI0706723A2 (pt) | 2011-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Creuwels et al. | The pulmonary surfactant system: biochemical and clinical aspects | |
| Cochrane et al. | The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. | |
| CA2575513C (fr) | Composition comprenant un tensioactif pulmonaire et un peptide derive de tnf | |
| AU734122B2 (en) | Compositions for the treatment of ARDS or IRDS containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4- (difluoromethoxy)benzamide and lung surfactant | |
| Herting et al. | Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia | |
| EP1216052A1 (fr) | Combinaison de c1-inh et d'un agent tensioactif pulmonaire pour le traitement des troubles respiratoires | |
| RU2533450C9 (ru) | Терапевтическая комбинация, содержащая легочный сурфактант и стероид | |
| DE60217060T2 (de) | Pharmazeutische Zusammensetzungen, die Lungensurfactants und ein Polymyxin umfassen und verbesserte Oberflächenspannung-senkende Eigenschaften haben | |
| JP2002529394A (ja) | 肺サーファクタント組成物を含有する治療セット | |
| PT89802B (pt) | Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas | |
| US20070244045A1 (en) | Treatment of Acute Respiratory Distress Syndrome | |
| CA2637644A1 (fr) | Traitement de syndromes de detresse respiratoire aigus | |
| Holm et al. | Designer surfactants: the next generation in surfactant replacement | |
| Lal et al. | Surfactant respiratory therapy using Surfaxin/sinapultide | |
| Suresh et al. | Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents? | |
| Donn | Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome | |
| JP4559731B2 (ja) | 肺サーファクタントの新規使用 | |
| Willson | Calfactant | |
| Anderson et al. | Effects on experimental acute lung injury 24 hours after exogenous surfactant instillation | |
| Spragg et al. | Surfactant Replacement in Patients with Ards: Results of Clinical Trials | |
| Du et al. | Extracorporeal membrane oxygenation (EMCO) is an optimal method to cure the pneumonia caused by endotoxin in mice | |
| Erçin et al. | New Generation Surfactants, Are They A Hope For Better Outcomes? | |
| US20210121525A1 (en) | Silk fibroin-containing composition and methods of use thereof | |
| Vidyasagar | Surfactant in respiratory distress syndrome | |
| Thomas et al. | Surfactant Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |